A
Anette Duensing
Researcher at University of Pittsburgh
Publications - 71
Citations - 5945
Anette Duensing is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Imatinib mesylate & Centrosome. The author has an hindex of 30, co-authored 69 publications receiving 5519 citations. Previous affiliations of Anette Duensing include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
p21(Waf1/Cip1) deficiency stimulates centriole overduplication.
TL;DR: It is shown that knock-down of p21 protein expression in murine myeloblasts can stimulate excessive centriole numbers in the presence of only one or two mature centrioles, and that aberrant centrosome numbers cannot solely be explained by polyploidization as suggested by previous studies.
Journal ArticleDOI
Mutations in BRCA2 and taxane resistance in prostate cancer
Cathleen Nientiedt,Martina Heller,Volker Endris,Anna-Lena Volckmar,Stefanie Zschäbitz,María A. Tapia-Laliena,Anette Duensing,Dirk Jäger,Peter Schirmacher,Holger Sültmann,Albrecht Stenzinger,Markus Hohenfellner,Carsten Grüllich,Stefan Duensing +13 more
TL;DR: There is overall a significant correlation between BRCA2 inactivation and a poor response rate to docetaxel, and the results suggest that a close oncological monitoring of patients with BRCa2 mutations for taxane resistance is warranted.
Journal ArticleDOI
A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention
TL;DR: Indirubin-derived compounds that have been chemically modified to be inactive as kinase inhibitors still significantly reduced centrosome amplification, suggesting that these compounds are potentially useful for the chemoprevention of centrerosome-mediated cell division errors and malignant progression in neoplasms in which the AhR is overexpressed.
Journal ArticleDOI
Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells
David Reynoso,Laura K. Nolden,Dan Yang,Sarah N. Dumont,Anthony P. Conley,A. G. Dumont,Kim Zhou,Anette Duensing,Jonathan C. Trent +8 more
TL;DR: The antitumor effects of the pro‐apoptotic Bcl‐2/Bcl‐xL inhibitor ABT‐737 are examined alone and in combination with imatinib to enhance imatin ib‐induced cytotoxicity and overcome imatinIB‐resistance in GIST cells.
Journal ArticleDOI
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
Xin Chen,Christof Bernemann,Yuri Tolkach,Martina Heller,Cathleen Nientiedt,Michael Falkenstein,Esther Herpel,Maximilian Jenzer,Carsten Grüllich,Dirk Jäger,Holger Sültmann,Anette Duensing,Sven Perner,Marcus V. Cronauer,Carsten Stephan,Jürgen Debus,Andres Jan Schrader,Glen Kristiansen,Markus Hohenfellner,Stefan Duensing +19 more
TL;DR: Prostate cancer cells with high nuclear AR-V7 protein expression can be detected in a substantial proportion of tumors at the time of radical prostatectomy and is associated with an unfavorable prognosis for BCR-free survival in a high-risk patient cohort including a subgroup of patients selected to receive adjuvant treatment.